At-Home Skyrizi Is a Channel Switch, Not a Demand Curve — and Option Care Health's $5.8B Takeout Already Priced the Shrinking Infusion Pool

The new subcutaneous induction regimen lets patients inject 720 mg at home at weeks 0, 2, 4 and 8, then continue on the same on-body injector every eight weeks from week 12. The intravenous start — 600 mg in weeks 0, 4 and 8 — remains on the label, so AbbVie added a home route rather than converting a mandatory one. That distinction matters: nothing forces a patient, a prescriber or a payer to move.

Before October 23, a Crohn's patient on Skyrizi started with three intravenous infusions administered in an infusion center or physician's office, with the drug bought and billed on the medical benefit. After it, the drug is dispensed by a specialty pharmacy and injected at home, so the prescription moves from the medical benefit to the pharmacy benefit and the administration fee disappears with it. That is the entire mechanism of the approval: a re-routing of existing revenue, plus the removal of the three-visit hurdle that was the most concrete reason to refuse Skyrizi.

Sizing the two sides settles the argument before it starts. Skyrizi did $8.54 billion of U.S. net revenue in the first half of 2026, roughly $17.1 billion annualized, while the largest listed home infusion operator took $1.44 billion of revenue and $267 million of gross profit in the second quarter alone. The entire enterprise value buyers agreed to pay for Option Care Health on October 6 — about $5.8 billion — equals roughly a third of one year of U.S. Skyrizi revenue. A channel that small cannot swing a $17 billion franchise, no matter how many visits it loses.

There is a serious counter-argument here, and it deserves to be stated plainly. McKesson's own rationale for paying up cites the increasing need for alternate infusion services and the shift of complex therapies into lower-cost community settings. A strategic buyer is paying a 37% premium for the channel in the same month that self-administration starts eroding one of its administration categories. If the channel proves durable and the at-home label stalls, today's pessimism about the pool will look wrong.

The upstream layer was resolved before the label arrived. West Pharmaceutical Services agreed in December 2025, and announced on January 12, 2026, to sell all manufacturing and supply rights for its SmartDose 3.5 mL on-body delivery system — the wearable platform behind Skyrizi's injector — to AbbVie for $112.5 million. The deal closed July 1, 2026 for about $136 million in cash, and West Pharmaceutical Services expects to book a $55 million to $60 million pre-tax gain in the third quarter of 2026.

The signal matters more than the dollars. A company does not buy the rights to a wearable injector platform and hand over the facilities nine months before winning a label that makes the device the delivery mechanism for a whole indication. AbbVie had already decided that self-injection volume was core to the franchise, which is exactly why the at-home label should be read as a prepared channel rather than a new strategy.

Johnson & Johnson won FDA approval on March 20, 2025 for Tremfya with both subcutaneous and intravenous induction in adults with moderately to severely active Crohn's disease. AbbVie spent nineteen months without parity, and on October 23, 2026 closed the access gap in a market where it already holds the scale advantage: Skyrizi alone generated $17.56 billion globally in 2025, against $15.7 billion of Johnson & Johnson immunology product sales that fell 11.8%.

Here is the part that decides whether the label is accretive. When a biologic moves from buy-and-bill to a pharmacy dispense, the deduction changes shape: medical-channel discounts give way to rebate economics in the commercial pharmacy benefit, and for Medicare, self-administered biologics such as Skyrizi sit in Part D while intravenous doses sit in the medical benefit. So AbbVie is likely trading a lower administrative burden for a lower net price per dose, and the access and volume gain has to outrun that dilution.

The disciplined way to hold this view is to stop treating the approval as a revenue event and start treating it as a channel specification. Ask two questions on October 30: what management assumes about at-home start rates, and what it assumes about the net price of a dose that moves from the medical benefit to the pharmacy benefit. Those two assumptions, not the approval, decide whether this franchise keeps the margin it just re-routed.